JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 45(2011) N 5 p. 797-803;
M.A. Emelyanova1, F.A. Amosenko2, A.V. Chudinov1, S.A. Surzhikov1, T.P. Kazubskaya3, L.N. Lyubchenko3, T.V. Nasedkina1*

Detection of KRAS Mutations in Tumor Cells Using Biochips

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
2Research Centre for Medical Genetics, Russian Academy of Medical Sciences, Moscow, 115478 Russia
3Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478 Russia

*nased@eimb.ru
Received - 2010-12-08; Accepted - 2011-01-20

Somatic mutations in the KRAS gene are important markers of some types of tumors, for example, pancreatic cancer, and may be useful in early diagnostics. A biochip has been developed which allows determining most frequent mutations in 12, 13, and 61 codons of the KRAS gene. To increase the sensitivity of the method and to enable the analysis of minor fractions of tumor cells in clinical samples, the method of blocking wild type sequence PCR amplification by LNA-oligonucleotides has been used. The product of LNA-clamp PCR was further hybridized with oligonucleotide probes, immobilized on the biochip. The biochip was tested with 42 clinical DNA samples from patients with pancreatic cancer, mostly duct adenocarcinomas. As reference methods, RFLP analysis and sequencing were used. The developed approach allows detecting somatic mutations in the KRAS gene if the portion of tumor cells with mutation is at least 1% of the whole cell population.

somatic mutations, tumor, KRAS gene, biochips



JMB-FOOTER RAS-JOURNALS